Changes

{{Under Construction}}

{{Under Construction}}

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Acute Basophilic Leukemia]].

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Acute Basophilic Leukemia]].

}}</blockquote>

}}</blockquote>

==Primary Author(s)*==

==Primary Author(s)*==

__TOC__

__TOC__

==Cancer Category/Type==

==Cancer Category / Type==

[[AML|Acute Myeloid Leukemia]]  

[[AML|Acute Myeloid Leukemia]]  

==Definition / Description of Disease==

==Definition / Description of Disease==

Acute basophilic leukemia is a rare subtype of acute myeloid leukemia (AML) with primary differentiation to basophils<ref name=":0">Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. IARC Press: Lyon, France, p164-165.</ref>.  This is a distinct entity in the World Health Organization (WHO) classification system within the section of [[Acute Myeloid Leukemia (AML), Not Otherwise Specified]]<ref name=":0" />.  This entity does ''not'' meet the criteria for inclusion in any of the other AML groups (i.e. AML with Recurrent Genetic Abnormalities, AML with Myelodysplasia-Related Changes, or Therapy-Related Myeloid Neoplasms).  Due to the rarity of this disease, consistent genetic diagnostic criteria have not been established.  Clinical progression is often rapid and associated with poor prognosis<ref name=":1">{{Cite journal|last=Kritharis|first=Athena|last2=Brody|first2=Judith|last3=Koduru|first3=Prasad|last4=Teichberg|first4=Saul|last5=Allen|first5=Steven L.|date=2011|title=Acute basophilic leukemia associated with loss of gene ETV6 and protean complications|url=https://www.ncbi.nlm.nih.gov/pubmed/21576634|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=29|issue=21|pages=e623–626|doi=10.1200/JCO.2010.34.5710|issn=1527-7755|pmid=21576634}}</ref>.

Acute basophilic leukemia is a rare subtype of acute myeloid leukemia (AML) with primary differentiation to basophils<ref name=":0">Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. IARC Press: Lyon, France, p164-165.</ref>.  This is a distinct entity in the World Health Organization (WHO) classification system within the section of [[HAEM4:Acute Myeloid Leukemia (AML), Not Otherwise Specified]]<ref name=":0" />.  This entity does ''not'' meet the criteria for inclusion in any of the other AML groups (i.e. AML with Recurrent Genetic Abnormalities, AML with Myelodysplasia-Related Changes, or Therapy-Related Myeloid Neoplasms).  Due to the rarity of this disease, consistent genetic diagnostic criteria have not been established.  Clinical progression is often rapid and associated with poor prognosis<ref name=":1">{{Cite journal|last=Kritharis|first=Athena|last2=Brody|first2=Judith|last3=Koduru|first3=Prasad|last4=Teichberg|first4=Saul|last5=Allen|first5=Steven L.|date=2011|title=Acute basophilic leukemia associated with loss of gene ETV6 and protean complications|url=https://www.ncbi.nlm.nih.gov/pubmed/21576634|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=29|issue=21|pages=e623–626|doi=10.1200/JCO.2010.34.5710|issn=1527-7755|pmid=21576634}}</ref>.

==Synonyms / Terminology==

==Synonyms / Terminology==

</blockquote>

</blockquote>

==Individual Region Genomic Gain/Loss/LOH==

==Individual Region Genomic Gain / Loss / LOH==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>

</blockquote>

</blockquote>

==Gene Mutations (SNV/INDEL)==

==Gene Mutations (SNV / INDEL)==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>